William Le
Senior Director of Clinical Operations Clarity Pharmaceuticals
Thursday 17th September 2026
Panel Discussion: Future Directions – Where Does the Chain Break? A Collective Assessment of the Industry’s Most Critical Unresolved Supply Chain Challenges & the Priorities That Must Be Addressed Collectively Before the Next Wave of Approvals Arrives
4:00 pm
- Across the two days, which single supply chain or manufacturing bottleneck has emerged as most urgent, and what does a credible industry-level response to it look like?
- Where does the field realistically stand on isotope supply security in five years, and which production pathways, technologies, and investment models will determine whether commercial-scale alpha therapy becomes a reality?
- How must the relationship between biopharma, CDMOs, isotope providers, logistics specialists, and clinical sites evolve structurally to one that can reliably deliver therapies to patients at scale?
Thursday 17th September 2026
Aligning Manufacturing Output with Clinical Site Expectations to Improve Treatment Throughput
1:50 pm
A 20-minute case study presentation exploring real-world site coordination challenges, followed by a 20 minute facilitated roundtable discussion where attendees share experiences and strategies to improve site readiness and treatment delivery.
- Defining what clinical sites require from manufacturers, including format, delivery method, documentation, and support
- Coordinating chain of custody and ensuring product integrity from production through to administration
- Identifying bottlenecks at the clinical site level, including patient throughput and handling constraints
- Improving collaboration between CMC teams and clinical stakeholders to enable smoother delivery
